-
Announcement of the State Food and Drug Administration on the conversion of Liubo Zhangmin liniment prescription drugs into non-prescription drugs (No. 93 of 2021)
Time of Update: 2021-11-14
Variety non-prescription drug instruction sheet template (82 ml) State Food and Drug Administration July 9, 2021 State Drug Administration Announcement No.
-
The transformation to "intelligent manufacturing" has become the general trend of the development of the pharmaceutical industry!
Time of Update: 2021-11-14
For Hongdou Group's huge investment in building a smart factory project for high-end complex anti-tumor preparations, the industry believes that this is mainly because the pharmaceutical industry is facing the challenge of large-scale production.
-
[2021 ASH] The clinical progress of Oribatinib, a new anti-drug-resistant leukemia drug, was selected as an oral report at the ASH annual meeting for the fourth time. A total of three studies of this product were selected
Time of Update: 2021-11-14
Oribatinib (HQP1351) is the key to the treatment of tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I mutant chronic myelogenous leukemia (CML-CP and CML-AP) subjects The latest results of the phase II trial 3598 Poster display Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetic (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)
-
What is Pfizer still planning to return to the world's No. 1 mRNA vaccine?
Time of Update: 2021-11-14
In the financial report, Pfizer raised its full-year sales forecast for Comirnaty's new crown vaccine by 7% to approximately US$36 billion .
Pfizer also announced the latest developments in six key R&D pipeline products including the new crown vaccine, gene therapy pipeline, PDE4 inhibitor, TL1A inhibitor, IFN-β inhibitor and oral COVID-19 drugs .
-
Cumulative savings of about 250 billion yuan!
Time of Update: 2021-11-14
The implementation of centralized procurement has significantly reduced the prices of commonly used drugs for the treatment of common diseases such as high blood pressure, diabetes, hyperlipidemia, cancer, and mental diseases, with an average drop of more than 50%.
-
National Medical Insurance Administration: In principle, all national drug procurement agreements should continue to carry out centralized procurement after the expiration of the agreement
Time of Update: 2021-11-14
44 The medical insurance bureaus of all provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps: In order to implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" (Guobanfa [2021] No.
-
Announcement of the State Food and Drug Administration on the publication of the list of medical pharmacy professional publications that allow the publication of prescription drug advertisements (No. 64 of 2021)
Time of Update: 2021-11-14
According to the "Advertising Law of the People's Republic of China", the National Health Commission of the People's Republic of China agreed to include the "Journal of Alzheimer's Disease and Relate
-
Osaikang's second biological Class 1 new drug storms the tens of billions of ophthalmology market
Time of Update: 2021-11-14
Figure 1: The latest product information declared by OsaikonSource: CDE official websiteThe announcement mentioned that ASKG712 injection can block the VEGF/VEGFR signal and effectively control the formation of new blood vessels, while also inhibiting the Ang-2 signal to improve blood vessel stability and reduce retinal inflammation, and consolidate the therapeutic effect of anti-VEGF-A .
-
In order to ensure drug supply and stable prices, relevant departments in my country are strengthening the security measures for listed drugs
Time of Update: 2021-11-14
Since 2021, the leading department of the consultation and linkage mechanism for the supply and guarantee of shortage of medicines at the national and provincial levels has worked with relevant units to focus on the implementation of the national shortage of medicines list and the key monitoring list of clinically necessary and easy-to-shortage medicines, and continue to promote the sharing of medicine-related information.
-
Yangtze River hits 1 billion injections!
Time of Update: 2021-11-14
Since the beginning of this year, Yangtze River has received 19 injections, covering multiple therapeutic areas such as anti-tumor drugs, anesthetics, and contrast agents .
0 Chinese Drug Evaluation DatabaseSince the beginning of this year, Yangtze River has received 19 injections, covering multiple subcategories such as anti-tumor drugs, anesthetics, and contrast agents.
-
Yuandong Bio-Repaglinide Metformin Tablets Obtained "Drug Registration Certificate"
Time of Update: 2021-11-14
Repaglinide and metformin tablets are compound preparations, the components of which are repaglinide and metformin hydrochloride .
It is suitable for patients who have been treated with glinide and metformin hydrochloride in combination, or treated with glinide or metformin hydrochloride monotherapy.
-
Throat diseases hit the season with high incidence, and pharmaceutical companies are rushing to grab the 5 billion throat Chinese patent medicine market
Time of Update: 2021-11-13
For example, according to relevant data, in 2020, the sales of terminal throat Chinese patent medicines in physical pharmacies in Chinese cities will exceed 4.
In the field of throat Chinese patent medicines, representative companies include Yangzijiang Pharmaceutical, Guilin Sanjin, Golden Throat, Guilong Pharmaceutical, and Jiangzhong Pharmaceutical .
-
Roche/Regeneron Ronapreve approved in Japan for preventive treatment of symptomatic COVID-19
Time of Update: 2021-11-13
Recently, Chugai Pharma, a Japanese pharmaceutical company controlled by Roche, recently announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved the antibody cocktail therapy Ronapreve (casirivimab and imdevimab, formerly known as: REGN-COV2) as a new indication : Used to prevent symptomatic SARS-CoV-2 infection (COVID-19) .
-
The environmental protection storm in the pharmaceutical industry continues, and it has become an inevitable trend to accelerate the transition to "green"
Time of Update: 2021-11-13
Recently, the Shenyang Municipal Bureau of Ecology and Environment released the "Shenyang Municipality’s Second Round of Provincial-level Ecological Environmental Protection Inspectors' Rectification Plan", and the pollution problem of a pharmaceutical company was once again exposed .
-
"Latest Breaking News" Mentor Program Covers WeChat QQ "Mobile Sohu.com"
Time of Update: 2021-11-13
Many times we can enrich ourselves by learning various skills.
. Step 3: Kill 1 pattern is like killing all odd, all even, all small, all big, all quality, all combined with small probability.
Sometimes other people's experience will become our learning direction .
-
The world's first targeted human interleukin-5 antibody biologics approved for marketing, Xin Kelai debuts at the 4th CIIE
Time of Update: 2021-11-13
Shanghai, November 6, 2021/PRNewswire/ - Today, at the 4th China International Import Expo, Xinkelai (generic name: mepolizumab) became the world's first target approved for marketing The identity of human interleukin-5 (IL-5) antibody biologics was officially unveiled, hoping to provide new treatment options for Chinese patients and families affected by inflammatory diseases caused by eosinophilia .
-
The manufacturing method of Yongan Pharmaceutical's taurine obtained a patent certificate issued by the Japanese Patent Office
Time of Update: 2021-11-13
On November 5, Yongan Pharmaceutical issued an announcement stating that the manufacturing method of taurine had recently received a patent certificate issued by the Japanese Patent Office .
-
Gale and Suzhou Corning Jerry signed a global exclusive development agreement for ASC22 (Envolimab) for the treatment of hepatitis B and other viral diseases
Time of Update: 2021-11-13
Under the terms of the agreement, Corning Jerry Suzhou song ceremony to grant the development and commercialization ASC22 outside Greater China exclusive worldwide rights, authorized indications for all viral diseases, including hepatitis B, including .
-
A dazzling presence in the pharmaceutical industry: AI pharmaceuticals
Time of Update: 2021-11-13
According to the industry, traditional biopharmaceutical companies have pain points such as long research and development cycles, high failure rates, and high costs when conducting new drug research and development.
-
Supporting the submission of new drug applications this year, the key clinical trial results of innovative RNAi therapy are positive
Time of Update: 2021-11-13
The trial reached the primary endpoint, that is, nedosiran caused a statistically significant decrease in urine oxalate excretion (Uox) in patients with PH1 subtype compared with placebo .